ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AVBP · as of Sep 30, 2025
Ownership Breakdown
108
Institutional Holders
▲ 11 vs Q2
$712.38M
Total Inst. Value
▼ $19.66M vs Q2
46.57M
Shares Outstanding
freeFloat 63.93%
38.57M
13F Shares Held
▲ 4.94M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AVBP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
HHLR ADVISORS, LTD. pharmaceutical preparations | 4.48M | 10.70% | 10.70% | $82.74B | Nov 14, 2025 | — held |
INFINITUM ASSET MANAGEMENT, LLC pharmaceutical preparations | 3.87M | 9.23% | 9.23% | $71.38B | Nov 14, 2025 | ▲ 450.0K |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.70M | 8.84% | 8.84% | $68.33B | Nov 14, 2025 | ▲ 290.7K |
FMR LLC pharmaceutical preparations | 3.41M | 8.13% | 8.13% | $62.87B | Nov 13, 2025 | ▲ 1.35M |
ORBIMED ADVISORS LLC pharmaceutical preparations | 3.03M | 7.22% | 7.22% | $55.85B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 2.05M | 4.88% | 4.88% | $37.75B | Nov 12, 2025 | ▲ 207.8K |
VANGUARD GROUP INC pharmaceutical preparations | 2.03M | 4.84% | 4.84% | $37.44B | Nov 7, 2025 | ▲ 546.0K |
OCTAGON CAPITAL ADVISORS LP pharmaceutical preparations | 1.97M | 4.70% | 4.70% | $36.37B | Nov 14, 2025 | ▲ 25.0K |
NOVO HOLDINGS A/S pharmaceutical preparations | 1.94M | 4.63% | 4.63% | $35.83B | Nov 14, 2025 | ▲ 70.0K |
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 1.70M | 4.05% | 4.05% | $31.31B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+4.98M shares8
New Positions
first time holders5
Decreased
−392.6K shares0
Sold Out
fully exitedNet shares change (top 50)
+4.59M
+4.98M / −392.6K
Net new holders
+32
8 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AVBP insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
5
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
LaChapelle Robin Chief Operating Officer | Feb 2, 2026 | Award | 130,000 | $22.67 | $2.95M | 130.0K | Form 4 ↗ |
Lutzker Stuart President of R&D | Feb 2, 2026 | Award | 150,000 | $22.67 | $3.40M | 150.0K | Form 4 ↗ |
Kung Winston Chief Financial Officer | Feb 2, 2026 | Award | 140,000 | $22.67 | $3.17M | 140.0K | Form 4 ↗ |
Yao Zhengbin President and CEO | Feb 2, 2026 | Award | 550,000 | $22.67 | $12.47M | 550.0K | Form 4 ↗ |
Kastenmayer James Paul General Counsel | Feb 2, 2026 | Award | 130,000 | $22.67 | $2.95M | 130.0K | Form 4 ↗ |
HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10 percent owner | Dec 10, 2025 | Sale | 555,555 | $23.37 | $12.98M | 3.93M | Form 4 ↗ |
Parsey Merdad director | Jun 18, 2025 | Award | 15,502 | $24.89 | $385.8K | 15.5K | Form 4 ↗ |
Peterson Kristine director | Jun 18, 2025 | Award | 15,502 | $24.89 | $385.8K | 15.5K | Form 4 ↗ |
Hohneker John director | Jun 18, 2025 | Award | 15,502 | $24.89 | $385.8K | 15.5K | Form 4 ↗ |
Nolet Chris director | Jun 18, 2025 | Award | 15,502 | $24.89 | $385.8K | 15.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ArriVent BioPharma, Inc. Common Stock (AVBP) is primarily owned by institutional investors, who hold approximately 82.8% of total shares outstanding. Company insiders own approximately 36.07%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of ArriVent BioPharma, Inc. Common Stock is HHLR ADVISORS, LTD., holding approximately 4.48 million shares — equal to 10.70% of outstanding shares — as of September 30, 2025.
A total of 108 institutional investors currently hold AVBP stock, with a combined institutional value of approximately $712,380,918 as of the most recent 13F filing period.
Frequently asked questions
AVBP ownershipArriVent BioPharma, Inc. Common Stock (AVBP) is primarily owned by institutional investors, who hold approximately 82.8% of shares. The largest shareholder is HHLR ADVISORS, LTD. with a 10.70% stake. Company insiders hold 36.07%. Data sourced from SEC Form 13F as of September 30, 2025.